Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130482 | 1.00 | SLC6A4 (0.52) | SLC6A4ACHEBCHELMNAMAPK1 | |
| SCHEMBL468409 | 0.92 | SLC6A4 (0.52) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL30130512 | 0.92 | SLC6A4 (0.52) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL3408176 | 0.90 | SLC6A4 (0.56) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL30130509 | 0.90 | SLC6A4 (0.56) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL30130500 | 0.89 | SLC6A4 (0.52) | SLC6A4ACHEBCHE | |
| SCHEMBL3405322 | 0.89 | SLC6A4 (0.52) | SLC6A4ACHEBCHE | |
| SCHEMBL21065413 | 0.87 | SLC6A4 (0.47) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL3404814 | 0.86 | SLC6A4 (0.52) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL30130448 | 0.86 | SLC6A4 (0.52) | SLC6A4ACHELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | claimed |
| EP-1660130-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. Lundbeck A/S (DK) | 2006-05-31 | — | — | EP | claimed |
| EP-1301502-B1 | COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | LUNDBECK & CO AS H (DK) | 2005-05-18 | — | — | EP | claimed |
| WO-2005018676-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. LUNDBECK A/S (DK) | 2005-03-03 | — | — | WO | claimed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170181989-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-06-29 | — | — | US | disclosed |
| US-20150099015-A1 | Sorbic and Benzoic Acid and Derivatives Thereof Enhance the Activity of a Neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2015-04-09 | — | — | US | disclosed |
| US-20100189818-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | US | disclosed |
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | disclosed |
| EP-1660130-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. Lundbeck A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| US-6921774-B2 | Compounds and their use as glycine transport inhibitors | H. LUNDBECK A/S (DK) | 2005-07-26 | — | — | US | disclosed |
| EP-1301502-B1 | COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | LUNDBECK & CO AS H (DK) | 2005-05-18 | — | — | EP | disclosed |
| WO-2005018676-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. LUNDBECK A/S (DK) | 2005-03-03 | — | — | WO | disclosed |
| US-20030181445-A1 | Novel compounds and their use as glycine transport inhibitors | H. LUNDBECK A/S (DK) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181445-A1 | Novel compounds and their use as glycine transport inhibitors | SLC1A5, SLC7A1, SLC7A11 | SLC6A4 75/4885ACHE 4176/4885BCHE 2384/4885 |
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | SLC6A4, SLC6A7, SLC6A5 | SLC6A4 1/4885ACHE 3392/4885BCHE 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.